-
2 weeks ago | 
ajmc.com | Pearl Steinzor |Mary Caffrey |Constance Blunt
Screening coverage is not just about medical tests, but about maintaining patient trust, reducing long-term health care costs, and ensuring accessible preventive care, says Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center. This transcript was lightly edited; captions were auto-generated. TranscriptIf insurance plans could eliminate free preventive screenings (employer or Medicaid), do you anticipate there would be fewer screenings? What kind of impact would this have?
-
2 weeks ago | 
ajmc.com | Julia Bonavitacola |Pearl Steinzor |Samir Shah
Samir Shah, MD, MMM, FACR, spoke about his collaboration with University Hospitals (UH) Cleveland to incorporate more artificial intelligence (AI) tools that could help identify early nodules of lung cancer. The future of thoracic care could rely on these tools to help improve prognosis in lung cancer. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptCan you share how qXR-LN works and its significance for thoracic specialists?
-
3 weeks ago | 
ajmc.com | Pearl Steinzor |Adam Colborn
The Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025 is a bipartisan bill that would ensure that Americans continue to have reliable access to testing and treatment for respiratory illnesses, including COVID-19, respiratory syncytial virus (RSV), the flu, and other potential future threats to public health, Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP), explained.
-
3 weeks ago | 
ajmc.com | Pearl Steinzor |Dirk Arnold |Vincent J. Picozzi |Danny Rischin
Oncology professionals reflect on the unique value of attending the American Society of Clinical Oncology (ASCO) annual meeting—from discovering new clinical trial results to reconnecting with peers from around the world. With major practice-changing research and global thought leadership in one place, ASCO continues to be a can't-miss event for the cancer care community.
-
3 weeks ago | 
ajmc.com | Julia Bonavitacola |Pearl Steinzor |Samir Shah
Samir Shah, MD, MMM, FACR, chief medical officer of Qure.ai, spoke about his work with the company, which informs stakeholders about the benefits of artificial intelligence (AI) in radiology, specifically in catching nodules that could turn into lung cancer. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptHow is Qure.ai working to help bring more AI solutions to health care sites across the globe? We've been working with multiple teams.
-
3 weeks ago | 
ajmc.com | Pearl Steinzor |Mary Caffrey |Constance Blunt
The mobile health care initiative represents a innovative model of community-based health care that addresses systemic access challenges by bringing services directly to those who need them most, explains Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center. This transcript was lightly edited; captions were auto-generated. TranscriptWhen patients know that certain screenings are free, does it make a difference in their willingness to be screened?
-
3 weeks ago | 
ajmc.com | Pearl Steinzor
Patients with generalized pustular psoriasis (GPP) have nearly 5 times the risk of all-cause mortality at 1 year and 4 times the risk over long-term follow-up compared with the general population, according to an observational US claims data analysis study published in the Journal of Psoriasis and Psoriatic Arthritis.1 “This underscores the need for improved treatment options, expanded use of the available options, and more effective clinical management of acute, generalized forms of...
-
3 weeks ago | 
ajmc.com | Pearl Steinzor
A blood-based circulating tumor DNA (ctDNA) test detected colorectal cancer (CRC) with 79.2% sensitivity and 91.5% specificity, according to a recent prospective study.1 These findings suggest the investigational test may be a viable noninvasive screening option, although its ability to detect advanced precancerous lesions remains limited. The population-based, observational study is published in JAMA.
-
3 weeks ago | 
ajmc.com | Julia Bonavitacola |Pearl Steinzor
The recent approval of albuterol/budesonide could change the way that mild asthma is treated in patients, explained Reynold Panettieri, Jr, MD, vice chancellor for Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptHow will the combination of albuterol/budesonide change the treatment of mild asthma? This is a real game changer. Why?
-
3 weeks ago | 
ajmc.com | Julia Bonavitacola |Pearl Steinzor |Samir Shah
Samir Shah, MD, MMM, FACR, chief medical officer of Quir.ai, discussed the developments in artificial intelligence (AI) that have occurred in the thoracic space and how these new developments can help both patients and clinicians in the long run. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptCan you give an overview of the current uses of AI in thoracic care? Yes, I can. Right now, AI has been used in 2 different areas, and being used. First in robotics.
